LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Начало・Списък с акции・Innoviva Inc

Innoviva Inc

Затворен

СекторЗдравеопазване

20.63 -1.76

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.58

Максимум

21.03

Ключови измерители
By Trading Economics
Приходи	26M 90M
Продажби	7.5M 108M
P/E Средно за сектора	13.374 80.03
EPS	0.385
Марж на печалбата	83.403
Служители	127
EBITDA	25M 108M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+52.38% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	519M 1.7B
Предишно отваряне	22.39
Предишно затваряне	20.63

Настроения в новините

By Acuity

50%

23 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

18.57 / 18.75 Подкрепа & съпротива

Innoviva Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.12.2025 г., 22:13 ч. UTC

Печалби

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9.12.2025 г., 21:40 ч. UTC

Печалби

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9.12.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9.12.2025 г., 16:57 ч. UTC

Значими двигатели на пазара

Clear Secure Rises on Medicare Identity Verification Contract

9.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9.12.2025 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings Stake in Lenovo Now at 32.34%

9.12.2025 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9.12.2025 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9.12.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9.12.2025 г., 22:42 ч. UTC

Печалби

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9.12.2025 г., 20:28 ч. UTC

Пазарно говорене

Oil Futures Decline for Second Straight Session -- Market Talk

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Reports Voting Results From Special Meeting of Hldrs

9.12.2025 г., 20:26 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9.12.2025 г., 20:21 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9.12.2025 г., 19:52 ч. UTC

Печалби

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9.12.2025 г., 19:17 ч. UTC

Печалби

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.12.2025 г., 17:11 ч. UTC

Печалби

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Innoviva Inc Прогноза

Ценова цел

By TipRanks

52.38% нагоре

12-месечна прогноза

Среден 32 USD 52.38%

Висок 45 USD

Нисък 17 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Innoviva Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Innoviva Inc през последните 3 месеца.

Техническа оценка

By Trading Central

18.57 / 18.75Подкрепа & съпротива

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

23 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.